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Abstract
Background: Shikimic acid (SA) is utilized in the synthesis of oseltamivir-phosphate, an anti-influenza drug. In this 
work, metabolic engineering approaches were employed to produce SA in Escherichia coli strains derived from an 
evolved strain (PB12) lacking the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS-) but with 
capacity to grow on glucose. Derivatives of PB12 strain were constructed to determine the effects of inactivating aroK, 
aroL, pykF or pykA and the expression of plasmid-coded genes aroGfbr, tktA, aroB and aroE, on SA synthesis.
Results: Batch cultures were performed to evaluate the effects of genetic modifications on growth, glucose 
consumption, and aromatic intermediate production. All derivatives showed a two-phase growth behavior with initial 
high specific growth rate (μ) and specific glucose consumption rate (qs), but low level production of aromatic 
intermediates. During the second growth phase the μ decreased, whereas aromatic intermediate production reached 
its maximum. The double aroK- aroL- mutant expressing plasmid-coded genes (strain PB12.SA22) accumulated SA up to 
7 g/L with a yield of SA on glucose of 0.29 mol/mol and a total aromatic compound yield (TACY) of 0.38 mol/mol. 
Single inactivation of pykF or pykA was performed in PB12.SA22 strain. Inactivation of pykF caused a decrease in μ, qs, SA 
production, and yield; whereas TACY increased by 33% (0.5 mol/mol).
Conclusions: The effect of increased availability of carbon metabolites, their channeling into the synthesis of aromatic 
intermediates, and disruption of the SA pathway on SA production was studied. Inactivation of both aroK and aroL, and 
transformation with plasmid-coded genes resulted in the accumulation of SA up to 7 g/L with a yield on glucose of 
0.29 mol/mol PB12.SA22, which represents the highest reported yield. The pykF and pykA genes were inactivated in 
strain PB12.SA22 to increase the production of aromatic compounds in the PTS- background. Results indicate 
differential roles of Pyk isoenzymes on growth and aromatic compound production. This study demonstrated for the 
first time the simultaneous inactivation of PTS and pykF as part of a strategy to improve SA production and its aromatic 
precursors in E. coli, with a resulting high yield of aromatic compounds on glucose of 0.5 mol/mol.
Background
The shikimic acid (SA) pathway is the common route
leading to the biosynthesis of aromatic compounds in
bacteria and in several eukaryotic organisms such as
ascomycetes fungi, apicomplexans, and plants [1,2]. In
Escherichia coli, the first step in this pathway is the con-
densation of the central carbon metabolism (CCM) inter-
mediates phosphoenol pyruvate (PEP) and erythrose 4-
phosphate (E4P) into 3-deoxy-D-arabinoheptulosonate
7-phosphate (DAHP) by the DAHP synthase (DAHPS)
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isoenzymes AroF, AroG, and AroH, coded respectively by
the aroF, aroG and aroH genes (Figure 1).
DAHP is converted to 3-dehydroquinate (DHQ) by
dehydroquinate synthase, coded by aroB. DHQ dehy-
dratase, coded by aroD, catalyzes the transformation of
DHQ into 3-dehydroshikimic acid (DHS). This com-
pound is reduced to SA by the shikimate dehydrogenase,
coded by aroE. In turn, SA is transformed to shikimate-3-
P (SHK-3P) by the shikimate kinase isoenzymes I and II,
coded by the aroK and aroL genes, respectively; SHK-3P
is then transformed to chorismic acid (CHA) (Figure 1).
SA is used as the precursor for the synthesis of a large
number of chemicals [3-5] and nowadays has gained
importance as the starting compound for the chemical
synthesis of the neuraminidase inhibitor oseltamivir
phosphate ((3R,4R,5S)-4-acetylamino-5-amino-3 (1-eth-
ylpropoxy)-1-cyclohexene-1-carboxylic acid, ethyl ester
phosphate (1:1)) known as Tamiflu®  and produced by
Roche Pharmaceuticals. This compound is currently
employed as an antiviral drug for the treatment of both
common seasonal influenza A and B virus infections [6,7]
and for the treatment of both the avian virus type H5N1
and A/H1N1 influenza infections. The latter has been
considered a new pandemic [8,9]. It has been estimated
that in the case of a global pandemic of influenza, the
present capacity of Tamiflu® production could be insuffi-
cient to protect large populations, particularly in devel-
oping countries [7,8]. Thus, alternative biotechnological
strategies with engineered strains to produce SA have
gained relevance.
Several metabolic engineering approaches have been
developed to obtain SA from E. coli by biotechnological
processes as an alternative to its limited and costly extrac-
tion procedures from plants such as Illicium anisatum or
I. verum [3,5,9-11]. Previously developed approaches
involve E. coli derivatives with several genetic modifica-
tions in the CCM and SA pathways. CCM modifications
comprise inactivation of the PTS operon (ptsHIcrr),
expression of non-PTS glucose transporters like glucose
facilitators and transformation with plasmids carrying
Figure 1 Central carbon metabolism and shikimic acid pathways in E. coli PB12 strain lacking the PTS. Glucose transport and phosphorylation 
are performed by GalP and Glk, respectively [27]. Abbreviations: Glc, glucose; GalP, galactose permease; Glc-6-P, glucose-6-P; Glk, glucokinase; PEP, 
phosphoenol pyruvate; PYR, pyruvate; Ac-CoA, acetyl coenzyme-A; TCA, tricarboxylic acid cycle; OAA, oxaloacetate; PPP, pentose phosphate pathway; 
E4P, erythrose-4-P; DAHP, 3-deoxy-D-arabinoheptulosonate-7-P; DHQ, 3-dehydroquinic acid; DHS, 3-dehydroshikimic acid; SA, shikimic acid; S3P, shi-
kimate-3-P; EPSP, 5-enolpyruvylshikimate-3-phosphate; CHA, chorismic acid; QA, quinic acid; PCA, protocatehuic acid; GA, gallic acid. Genes and cod-
ed enzymes: tktA, transketolase I;pykF, pyruvate kinase I;pykA, pyruvate kinase II;ppsA, phosphoenolpyruvate synthase; aroF, aroG, aroH, DAHP synthase 
isoenzymes F, G and H, respectively; aroB, DHQ synthase; aroD, DHQ dehydratase; aroE, shikimate dehydrogenase; aroK, shikimate kinase I; aroL, shiki-
mate kinase II; aroA, EPSP synthase; aroC, chorismate synthase; aroZ, dehydroshikimate dehydratase; pobA, p-hydroxy-benzoate hydroxylase [32]. Con-
tinuous arrows represent unique reactions catalyzed by one or more enzymes; dotted lines or arrows represent two or more enzymatic reactions or 
incomplete characterized reactions.
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the tktA and ppsA genes, coding for transketolase I and
PEP synthase, respectively, to increase the availability of
intermediates E4P and PEP, respectively [3,4,12-18]. The
main modifications in the SA pathway include the partial
or total blockage of the SA flux into CHA. This has been
achieved by decreasing or completely eliminating the
synthesis of SHK-3P -by inactivating aroK  and aroL
genes- with the subsequent SA accumulation (Figure 1).
These modifications are commonly complemented with
the transformation of plasmid-coded feedback resistant
(fbr) AroF or AroG proteins (AroFfbr and AroGfbr, respec-
tively), required to avoid possible feedback inhibition in
the first step of the aromatic pathway catalyzed by
DAHPS isoenzymes. The rate-limiting enzyme DHQ
synthase, and shikimate dehydrogenase, which is feed-
back inhibited by SA [3,15], catalyze two reactions that
can be improved with the goal of increasing the synthesis
of SA. It has been proposed that high extracellular SA
concentration drives the transport of this compound into
the cells by the SA transporter ShiA (shiA). Higher intrac-
ellular SA accumulation reverts the reaction catalyzed by
aroE  to synthesize DHS, resulting in "hydroaromatic
equilibration" and by-productby formation, such as
quinic (QA) and gallic acids (GA) (Figure 1). Inactivation
of the ShiA transporter has been used as a strategy to
reduce the intracellular accumulation of DHS, QA, and
GA [3,4,15,19,20]. Engineered E. coli strains with several
of the genetic modifications described above have been
successfully applied to produce 71 g/L of SA with a yield
of 0.27 mol SA/mol glc and total aromatic compound
yield (TACY) (including SA, DHS and QA) of 0.34 mol
aromatic compounds/mol glc in 1-L fed-batch cultures
using mineral broth with 15 g/L yeast extract and glucose
addition to maintain a 55-170 mM concentration [4]. The
effects of carbon and phosphate limitations in chemostat
cultures on SA production have been studied elsewhere
[15,19].
Our group has been involved in the characterization of
E. coli strains lacking the phosphoenolpyruvate: carbohy-
drate phosphotransferase system (PTS-), such as strain
PB12 (PTS- glc+), which has been selected as an evolved
strain for growth rate recovery in a chemostat with glu-
cose fed at progressively faster rates [21,22]. This strain
utilizes galactose permease (GalP) and glucokinase (Glk)
to transport and phosphorylate glucose into glucose-6-P,
respectively (Figure 1). In addition, most of the glycolytic
and other CCM genes are upregulated in this derivative
as compared to its parental strains [21-25]. Further char-
acterization of this evolved strain has shown increased
PEP availability that can be redirected into the aromatic
p a t h w a y ,  a s  c o m p a r e d  t o  i s o g e n i c  P T S +  strains. PB12
strain has been modified for the high yield production of
aromatic compounds such as L-phenylalanine [26,27] and
L-tyrosine [28].
In this work, we report the construction of a SA over-
producing derivatives from the E. coli PB12 strain by
inactivation of the aroL and aroK genes and expressing in
plasmids different combinations of aroGfbr,  tktA,  aroE,
and aroB genes. The effects of single inactivation of either
pyruvate kinase (Pyk) I or II, coded respectively by pykF
and pykA, were also evaluated. This strategy was used to
achieve additional availability of PEP for the synthesis of
aromatic compounds and SA in the E. coli PB12 PTS-
glc+background.
Results and discussion
Inactivation of the genes coding for shikimate kinases I and 
II, and expression of the aroGfbr, tktA, aroB and aroE genes 
in plasmids in the PB12 strain background
The capacity of the E. coli PB12 (PTS- glc+) strain to pro-
duce SA was evaluated in 500 mL batch cultures in 1 L
fermentors grown in mineral broth supplemented with 25
g/L of glucose and 15 g/L of yeast extract. Specific growth
rate (μ), glucose consumption (qs) ,  S A pr oduct io n a nd
Table 1: Growth kinetic parameters for strain PB12 and SA-producing derivatives.
Strain/derivative μa
(h-1)
qsb
(millimol glc g DW-1 h-1)c
PB12 0.48 ± 0.02 5.17 × 10-6 ± 4.07 × 10-7
PB12.SA11 0.41 ± 0.00 2.03 × 10-6 ± 4.79 × 10-7
PB12.SA21 0.42 ± 0.02* 2.5 × 10-6 ± 8.55 × 10 × 10-7*
PB12.SA22 0.42 ± 0.01* 1.93 × 10-6 ± 5.9 × 10 × 10-7*
PB12.SA31 0.32 ± 0.02 7.76 × 10-6 ± 9.67 × 10-8
PB12.SA41 0.45 ± 0.03 2.58 × 10-6 ± 5.39 × 10-7
Values are the average of two independent experiments. a μ, specific growth rate; bqs, specific glucose consumption rate; cDW, dry cell weight. 
Mean values within each column with the same superscript (*) (P < 0.05) do not differ significantly with respect to the immediate parental 
strain (see Methods).Escalante et al. Microbial Cell Factories 2010, 9:21
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yield, as well as DAHP, DHS and GA concentrations were
evaluated during 50-h cultures (Table 1, Figure 2). Strain
PB12 reached an OD600 nm of 32, after 8 h of fermentation
with the consumption of 98.7% of added glucose. From
this time (8 h) to the end of the fermentation (50 h), a
decrease in biomass concentration was observed (Figure
2). Analysis of culture supernatants showed that as
expected, strain PB12 did not accumulate DAHP (Table 2,
Figure 3).
Similarly to strain PB12, cultures of strain PB12.SA11
(aroL- strain expressing aroGfbr, tktA and aroB from two
different plasmids) (see Methods, Figure 1 and Table 3)
also showed an exponential growth phase during the first
8-h cultivation interval as detected for strain PB12 (Fig-
ure 2). However, a significant decrease (P < 0.05), deter-
mined by the Tukey's Honestly Significant Difference
(HSD) test, was observed (see Methods) in both μ and qs
values (86% and 39%, respectively), when compared to
those recorded for strain PB12 (Table 1). From this
moment (8 h) the strain remained stationary. DAHP,
DHS, SA, and GA production was detected during the
exponential growth phase (Figures 3 and 4). Interestingly,
relatively constant concentration levels of all aromatic
intermediates were observed after glucose was com-
Table 2: Aromatic metabolites production and yields determined for strain PB12 and SA-producing derivatives.
Strain SA
(g/L)
SA yield
(mol SA/mol 
glc)
DAHP
(g/L)
DHS
(g/L)
GA
(g/L)
TACY1
(mol aromatic 
compounds/mol 
glc)
PB12 ND --- 0.044 ± 0.07 ND ND 0.00
PB12.SA11 2.82 ± 0.01 0.11 ± 0.00 1.71 ± 0.07 2.79 ± 0.21 0.21 ± 0.06 0.28
PB12.SA21 5.07 ± 0.00 0.21 ± 0.00 0.52 ± 0.00 2.49 ± 0.06* 0.14 ± 0.00 0.33*
PB12.SA22 7.05 ± 0.06 0.29 ± 0.00 0.81 ± 0.04 1.46 ± 0.14 0.08 ± 0.01 0.37*
PB12.SA31 4.35 ± 0.57 0.22 ± 0.04 3.03 ± 0.00 2.12 ± 0.02 0.23 ± 0.04 0.50
PB12.SA41 1.00 ± 0.36 0.03 ± 0.02 0.14 ± 0.00 0.79 ± 0.01 ND 0.07
Values are the average of two independent experiments. 1TACY, Total aromatic compound yield (combined DAHP, DHS, SA and GA molar 
yields); ND, Non-detected. Mean values within each column with the same superscript (*) (P < 0.05) do not differ significantly with respect to 
the immediate parental strain (see Methods).
Figure 3 DAHP and DHS concentrations in PB12 and SA-produc-
ing derivatives.
A
B
 PB12
 PB12.SA11
 PB12.SA21
 PB12.SA22
 PB12.SA31
 PB12.SA41
Figure 2 Biomass and glucose concentrations in PB12 and SA-
producing derivatives.
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pletely consumed. DAHP, DHS, and SA accumulated dur-
ing the first 26 h of cultivation; thereafter their
concentration remained constant at around 1.71, 2.8, and
2.8 g/L, respectively (Table 2,). SA yield on glucose was
0.11 mol SA/mol. GA concentration was lower than the
other aromatic intermediates; however, as in the case of
D H S ,  t h i s  s t r a i n  p r o d u c e d  h i g h e r  G A  c o n c e n t r a t i o n s
(approximately 0.3 g/L, Table 2, Figure 4), than the other
PB12 derivatives. It has been proposed that GA is formed
by the oxidation of DHS into a diketo intermediate proto-
catehuic acid (PCA) followed by its spontaneous aromati-
zation. Alternatively, this compound may result from the
dehydration of DHS followed by hydroxylation of the
intermediate PCA [29] (Figure 1). GA accumulation dur-
ing SA production has not been reported in either batch
or fed-batch cultures [4], but it has been detected in batch
and chemostat cultures under carbon-limited conditions
[15].
Plasmid-coded AroGfbr DAHPS avoided feedback
inhibition of the first reaction of the SA pathway by the
phenylalanine present in the yeast extract included in the
medium or produced by the cell. It has been reported that
DAHPS activity in vivo is limited by PEP and E4P avail-
ability and that maximum specific activity of DAHPS is
reached when the concentration of both intermediates is
increased [13,17]. It has also been reported that the pres-
ence of a plasmid-coded copy of tktA (coding for transke-
tolase I) causes an increase in E4P availability in strain
PB12 [21,22,25,30-32]. In addition, it is expected that the
Table 3: Strains and plasmids used and developed in this work.
Strain/derivative Relevant characteristics Reference
E. coli JM101 supE, thi, Δ(lac-proAB), F' [45]
E. coli JM101 aroK- E. coli JM101 aroKΔ::cm This work
E. coli aroB- E. coli K12 strain BW25113 ΔaroB::kan 
(JW3352)
[48]
E. coli aroE- E. coli K12 strain BW25113 ΔaroE::kan 
(JW3242)
[48]
E. coli PB28 PB12 ΔpykA::cat ΔpykF::gen [31]
E. coli PB12 JM101 Δ(ptsH-I-crr)::kan glc+ [18]
PB12.SA1 PB12 ΔaroL This work
PB12.SA11 PB12.SA1 pJLBaroGfbr tktA pTOPOaroB This work
PB12.SA2 PB12 ΔaroL ΔaroK::cm This work
PB12.SA21 PB12.SA2 pJLBaroGfbr tktA pTOPOaroB This work
PB12.SA22 PB12.SA2 JLBaroGfbr tktA pTOPOaroB aroE This work
PB12.SA3 PB12.SA2 ΔpykF::gen This work
PB12.SA31 PB12.SA3 pJLBaroGfbr tktA pTOPOaroB aroE This work
PB12.SA4 PB12.SA2 ΔpykA::gen This work
PB12.SA41 PB12.SA4 pJLBaroGfbr tktA pTOPOaroB aroE This work
E. coli TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(ara-leu)7697 galU galK rpsL endA1nupG
Invitrogen
Plasmids
pJLBaroGfbr tktA pJLBaroGfbr (aroGfbr expressed from the 
lacUV5 promoter, lacIq and tet genes (Tcr), 
pACYC184 replication origin) derivative, 
containing the tktA gene with its native 
promoter.
[21,47]
pCR®-Blunt II-TOPO® Plac lacZ-α ORF T7 promoter ccdB kan (Kmr) 
Zeocin pUC origin.
Invitrogen
pTOPO aroB pCR®-Blunt II-TOPO® containing the aroB 
gene
This work
pTOPO aroB aroE pTOPOaroB derivative containing the aroB 
and aroE genes
This workEscalante et al. Microbial Cell Factories 2010, 9:21
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presence of aroB in a multicopy plasmid (Figure 1) will
reduce the possible accumulation of DAHP [3,4].
Inactivation of aroL gene as part of a SA production
strategy has been previously described in the E. coli
W3110 aroL- strain (W3110 shik1) in chemostat cultures
that resulted in maximum SA yields on glucose of 0.02
and 0.05 mol/mol under carbon and phosphate limited
conditions that resulted in a maximum SA yield on glu-
cose of 0.2 mol/mol and 0.05 mol/mol, respectively
[15,19]. In the present study, strain PB12.SA11 yielded
0.11 mol SA/mol glc; however, maximum yields of SA on
glucose of 0.27 and 0.33 mol/mol have been reported for
another  E. coli strain (PTS- glf, glk, aroFfbr,  tktA, aroE,
aroK- aroL-) in 1-L and 10-L fed-batch cultures, respec-
tively [4], suggesting that the ΔaroL phenotype is in itself
insufficient to achieve high SA yields.
Strain PB12.SA21 (aroL- aroK- strain expressing plas-
mid coded aroGfbr tktA and aroB  genes) (Figure 1 and
Table 3) showed an exponential growth phase during the
first 8 h fermentation interval and a stationary stage simi-
lar to what was observed for PB12 and PB12.SA11 strains
(Figure 2). No significant differences (P < 0.05) were
observed in μ  and  qs  values between PB12.SA21 and
PB12.SA11 strains as a consequence of the inactivation of
the aroL and aroK genes (Table 1). DAHP, DHS, SA, and
GA production was also detected during the exponential
growth phase, but important differences were observed
(Figures 3 and 4). Compared to the PB12.SA11 derivative,
m a x i m u m  c o n c e n t r a t i o n s  o f  D A H P  a n d  G A  i n  t h e
PB12.SA21 strain were significantly lower (P < 0.05),
whereas no significant difference (P < 0.05) was observed
in the maximum concentration of DHS (Table 2, Figure
3). Furthermore, SA production was observed through-
out all the process (Figure 4). After 50 h of cultivation,
about 5.1 g/L of SA were detected with a yield on glucose
of 0.21 mol/mol. This result represents a significant
increase (P < 0.05) (80%) in both SA concentration and
yield, as a consequence of the double aroK- aroL- muta-
tions (Table 2, Figure 4). The concentrations of DAHP,
DHS (Figure 3) and SA obtained in strain PB12.SA11, as
compared to the ones recorded for the PB12.SA21 deriva-
tive, indicate an efficient flow of aromatic intermediates
from DAHP to SA. However, based on the still relatively
high DHS concentration observed, it appears that this
strain can further convert part of the remaining DHS to
improve SA concentration and yield.
Cultures of strain PB12.SA22 (aroK-  aroL-  strain
expressing aroGfbr, tktA, aroB and aroE from two differ-
ent plasmids) (T able 3, Figure 1) showed no significant
differences (P < 0.05) in μ and qs values with respect to
those for strain PB12.SA21 (Table 1). Glucose was totally
consumed in both strains only after 38 h of cultivation
(Figure 2). DHS was detected in a significantly (P < 0.05)
lower concentration than the previous derivative and SA
reached the highest concentration compared to all other
derivatives (Table 2, Figure 4). At the end of the fermenta-
tion, 7.1 g/L of SA were detected with a yield on glucose
of 0.29 mol SA/mol (39% increase in yield with respect to
the previous derivative) and a TACY value of 0.378 mol
aromatic compounds/mol glc (Table 2, Figure 4). Intro-
duction of a copy of the aroE gene in the multicopy plas-
mid pTOPO resulted in a more efficient conversion of
DHS into SA, probably as a consequence of a responsible
for the synthesis of DHS from SA [3,4,15,19,20]. Accord-
ingly, very small amounts of GA were produced during
the cultivation of this strain (Table 2, Figure 4).
Inactivation of the genes coding for pyruvate kinases I and 
II in the PB12SA.22 strain
Disruption of the pykF gene in strain PB12.SA22 gener-
ated the PB12.SA31 derivative (aroL-, aroK-, pykF- strain
expressing aroGfbr, tktA, aroB and aroE genes from two
different plasmids) (Figure 1 and Table 3). Cultures of this
strain showed the characteristic two-phase growth
behavior observed for the previous derivatives (Figure 2),
although significant (P < 0.05) differences were observed
in μ and qs values as compared to the PB12.SA22 pykF+
parental strain (Table 1). In addition, maximum biomass
concentration after 8 h of fermentation was only 33%
with respect to the one recorded for PB12.SA22 and, con-
trary to all other analyzed strains, glucose was not com-
Figure 4 SA and GA concentrations in PB12 and SA-producing 
derivatives.
A
B
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 PB12.SA11
 PB12.SA21
 PB12.SA22
 PB12.SA31
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pletely consumed after 50 h (Figure 2). DHS, GA, and
specially DAHP final concentrations were higher than
those obtained with the pykF+ parental strain, whereas
the final SA production and yield were lower (Table 2).
Importantly, the TACY value in this strain was 0.50 mol
aromatic compounds/mol glc (i.e., a 33% increment with
respect to PB12.SA22), the highest yield obtained when
compared to all previous PB12.SA derivatives (Table 2).
Inactivation of the pykA gene in strain PB12.SA22 gen-
erated the derivative PB12.SA41 (aroL-,  aroK-,  pykA-
strain expressing aroGfbr, tktA, aroB and aroE genes from
two different plasmids) (Table 3, Figure 1). Cultures of
this strain showed no-significant differences (P < 0.05) in
μ and qs values with respect to those recorded for the
parental strain PB12.SA22 pykA+ (Table 1). This strain
reached an OD600 nm of 14 after 20 h of fermentation;
however, an important decrease in growth was observed
from this moment to the end of the fermentation (Figure
2). This strain also showed the lowest production of
DAHP, DHS, and SA as compared to all other variants,
and no GA was detected (Table 2, Figures 3 and 4).
Pyruvate kinase isoenzymes Pyk I and Pyk II play a key
role in the glycolytic pathway, especially in overall carbon
metabolism in strains lacking PTS [33,34]. Pyk activity,
together with phospho-fructokinase I and glucokinase,
control the carbon flux through the glycolytic pathway
and catalyze the essentially irreversible trans-phosphory-
lation of PEP and ADP into PYR and ATP [33]. It has
been previously reported that inactivation of pykF  in
strain PB12 (PTS-glc+) results in an apparently slight
increase in the specific activity of Pyk A enzyme (13.5%)
[34]. Likewise, carbon flux analysis in this strain has
shown a flux increase through the Pyk AF enzymes in the
absence of PTS as compared to the wild-type strain
(JM101 PTS+) [23]. Furthermore, transcriptome analyses
in strain PB12 and in a phenylalanine overproducing
PB12 derivative have shown a slight upregulation of pykA
with respect to the wild type strain JM101, suggesting
that the overall activity of PyK isoenzymes present in the
PB12 strain is sufficient to convert PEP into PYR, at least
at similar rates as in JM101 [31,35]. These results suggest
that single inactivation of the pykF or pykA gene could be
an attractive strategy to increase the amount of PEP avail-
able for DAHP synthesis, without compromising the syn-
thesis of PYR and its flux to acetyl-CoA.
Interruption of either the pykF or pykA gene in the E.
coli strain PB12.SA22 demonstrated a differential role of
Pyk isoenzymes in overall cellular metabolism in this
strain which produces aromatic compounds. Disruption
of pykF in strain PB12.SA31 negatively affected growth,
glucose consumption, and SA accumulation with respect
to the PB12.SA22 pykF+ parental strain. Importantly, the
TACY value increased to 0.50 mol aromatic compounds/
mol glc in the pykF- strain, which is 33% higher than the
total yield observed for the parental strain PB12.SA22.
These results suggest that pykF inactivation apparently
increases PEP availability, which in turn is channeled into
the aromatic pathway, resulting in a higher TACY value.
Higher DAHP concentrations produced by the
PB12.SA31 derivative also indicate that in this genetic
background, DHQ synthase could be one of the limiting
steps for SA production. This explanation contravenes
the fact that this strain was transformed with a plasmid-
carrying aroB;  however, a previous report on the pro-
teomic response to pykF inactivation in E. coli BW25113
strain demonstrated the upregulation of all the genes of
the SA pathway, with the exception of aroB, during the
production of aromatic amino acids [33]. Therefore,
increasing the expression of the aroB gene, by substitu-
tion of its natural promoter for a stronger one, could be a
viable strategy to improve SA concentrations in strain
PB12.SA31.
Pyk activity plays a key role in cellular metabolism by
connecting glycolysis with amino acid and lipid biosyn-
thetic pathways [34,36,37]. Consequently, one remarkable
characteristic of Pyk isoenzymes is their allosteric
response to several effectors involved not only in central
carbon metabolism but also in global cellular metabo-
lism, among them, the glycolytic intermediate PEP
[34,38,39]. It has been proposed that Pyk isoenzymes are
involved in catabolite repression in E. coli glucose fer-
mentations [40]; however, no information is available to
correlate the specific role of individual Pyk isoenzymes in
global bacterial metabolism, particularly in strains
devoted to the production of aromatic compounds. Our
results demonstrate that inactivation of the pykA gene in
strain PB12.SA41 caused a negative effect on the produc-
tion of aromatic compounds, probably due to an
increased growth rate (Table 1). In addition, SA accumu-
lation and TACY were substantially reduced in this strain
as compared to the PB12.SA31 (pykF-) and PB12.SA22
(pykA+ pykF+) strains. The lack of pykF clearly reduced μ
and qs values in relation to the parental PB12.SA22 strain.
In addition, glucose was not completely consumed in
strain PB12.SA31 after 50 h, as compared to strain lack-
ing pykA, where it was completely consumed after 25 h
(Figure 2). Furthermore, the accumulation of aromatic
compounds was the highest in the strain lacking pykF,
while in the strain PB12.SA22, 37% of glucose was con-
verted into aromatic compounds; this amount increased
to 50% in strain PB12.SA31. Altogether, the result of dif-
ferentially inactivating the kinases I and II suggest that
the PykF isoenzyme may have a more relevant role in
global cellular processes than PykA in the derivatives
constructed under the growth conditions tested here,
since it seems that the absence of pykF apparently allowsEscalante et al. Microbial Cell Factories 2010, 9:21
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higher accumulation of PEP than the absence of pykA.
Importantly, pykF is apparently transcribed when grow-
ing on glucose from at least three different promoters in
strains JM101 and PB12, while pykA is apparently only
transcribed from two [41]. These results are in agreement
with previous observations which suggest that PykF plays
a more important role than PykA in strain JM101 (PTS+)
and other derivative strains lacking PTS, when growing
on glucose as the only carbon source [34].
Conclusions
E. coli PB12 (PTS- glc+) strain was used as the host for the
synthesis of SA. The derivative PB12.SA22 was obtained
by inactivation of both aroL and aroK genes, and trans-
formed with plasmids carrying aroGfbr tktA, aroB, and
aroE genes. This strain was capable of efficiently channel-
ing carbon from metabolites participating in the CCM
into the aromatic pathway for the synthesis of SA. Fer-
mentor cultures of PB12.SA22 strain in mineral broth
complemented with 25 g/L glucose and 15 g/L yeast
extract resulted in the production of 7 g/L of SA with a
yield of SA on glucose of 0.29 mol/mol and a TACY of
0.38 mol aromatic compounds/mol glc. Importantly, glu-
cose was totally consumed in strain PB12.SA22 after 48 h
of fermentation. It is known that PTS- strains are capable
of utilizing higher concentrations of glucose (100 g/L)
[42,43] and different carbon sources simultaneously with
glucose [29,31]. Therefore, experiments with higher glu-
cose concentrations, including fed-batch fermentations
should be performed to increase SA concentrations. In
fact, preliminary results, in which glucose concentration
in the medium was increased to 100 g/L, in a 500 mL
batch fermentor cultures with strain PB12.SA22, allowed
the production of 14 g/L of SA (unpublished results).
Single inactivation of either the pykF or pykA gene was
performed to further increase PEP availability for SA pro-
duction in strain PB12.SA22. Inactivation of these genes
demonstrated differential roles of Pyk isoenzymes in final
growth, glucose consumption, and production of aro-
matic intermediates and SA. The pykF- mutation present
in strain PB12.SA31 substantially affected biomass con-
centration, glucose consumption, and SA production,
suggesting a more important role of the PykF isoenzyme
in comparison to PykA, in these growing conditions. The
production of SA was reduced in this strain as compared
to strain PB12.SA22; however, it is notable that TACY
reached a value of 0.5 mol aromatic compounds/mol glc,
which was 33% higher than the one obtained in the
parental pykF+ strain. As far as we know, there are no
reports in which the utilization of a double PTS-, pykF-
derivative has been used to improve the production of SA
and its aromatic precursors [3,4,16-18,44]. Further
genetic modifications will be undertaken in this pykF-
derivative, such as the substitution of the aroB natural
promoter for another that allows its upregulation to avoid
the accumulation of the aromatic intermediate DAHP in
order to increase the production of SA. In addition, car-
bon flux could still be further modulated by reducing the
expression of pykA in the strain lacking pykF, to obtain a
higher accumulation of PEP to be channeled into the SA
pathway. The pykA gene in these E. coli derivatives, as
mentioned, is expressed from two different promoters
when glucose is utilized as the only carbon source [41].
Therefore, it could be possible to construct derivatives
lacking one of these two promoters to reduce the tran-
scription of pykA with the goal of increasing PEP concen-
tration.
This study demonstrated for the first time the simulta-
neous inactivation of PTS and pykF as part of a strategy to
improve SA production and its aromatic precursors in E.
coli, with the resulting high yield of 0.5 mol aromatic
compounds/mol glc.
Methods
Bacterial strains and plasmids
Bacterial strains and plasmids used in this work are listed
in Table 3. E. coli PB12, a derivative of strain JM101 [45],
was used as the parental strain to originate the interrup-
tions in aroL and aroK as well as the single interruption of
pykF  or  pykA. Amplification of target genes was per-
formed with Pfu DNA polymerase (Fermentas, Glen Bur-
nie, USA), according to recommendations by the supplier,
in a GeneAmp PCR System thermocycler (Perkin Elmer
Cetus, Norwalk, USA). Primer sets employed for amplifi-
cation of target genes are listed in Table s1 (see Addi-
tional file 1). The size of the PCR products was
determined by agarose gel electrophoresis. When
required, amplicons were purified by cutting the desired
band from the agarose gels and processed with a gel PCR
purification kit (Marligen Biosciences, Urbana-Pike-
Ijamsville, USA). The obtained derivative strains were
transformed with plasmids carrying the aroGfbr,  tktA,
aroB, and aroE genes (see below) for the construction of
SA producing strains.
Inactivation of the aroL gene
PB12.SA1 strain (aroL- derivative) (Table 3) was obtained
by the one-step inactivation procedure of chromosomal
genes by PCR products [46]. Primer sets used are listed in
Table s1 (see Additional file 1). The aroL  gene was
replaced by the ΔaroL::cat  cassette. Selection was per-
formed in chloramphenicol (Cm) containing Luria Ber-
tani (LB) plates. Inactivation of the aroL  gene in
chloramphenicol resistant (Cmr) colonies was confirmed
by PCR and the size of the PCR product was determined
by agarose gel electrophoresis. The Cm cassette was
deleted from the ΔaroL::cat construction, as previously
described [46], to facilitate subsequent gene inactivation;
the aroL- genotype was confirmed by PCR.Escalante et al. Microbial Cell Factories 2010, 9:21
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Page 9 of 12
Inactivation of the aroK gene
Strain PB12.SA2 (aroL-, aroK- derivative) (Table 3) was
constructed in a two-step procedure. First, the aroK gene
of E. coli JM101 strain was replaced by the ΔaroK::cat
cassette [46]. Selection was performed in Cm containing
plates and the inactivation of aroK in Cmr colonies was
confirmed by PCR. Second, strain PB12.SA1 was the
recipient of P1 phage lysate grown on the JM101 aroK
strain; the aroK- genotype was confirmed by PCR.
Inactivation of the pykF gene
PB12.SA22 strain was the recipient of P1 phage lysate of
E. coli PB28 (ΔpykF::gen) strain (Table 3). Transductants
were selected on gentamicin (Gm) plates and the inacti-
vation of pykF in Gmr colonies was confirmed by PCR;
the size of the PCR product was determined by agarose
gel electrophoresis. The resultant strain (aroL-,  aroK-,
pykF- derivative) was named PB12.SA31.
Inactivation of the pykA gene
PB12.SA4 strain (aroL-, aroK-, pykA-derivative) (Table 3)
was constructed by a modification of the one-step inacti-
vation procedure of chromosomal genes by PCR prod-
ucts [46]. Briefly, template plasmids pKD3, pKD4, or
pKD13, used to amplify FRT-resistance gene-FRT cas-
sette, only allowed the use of Cm or kanamycin (Km) as
selection markers [46]; however, PB12.SA2 carried both
resistance genes as a consequence of previous genetic
modifications [31]. For this reason, a primer set was
designed (Table s1, see Additional file 1), for priming the
Gmr cassette flanked by the entire FRT sequence and
homology regions for the pykA gene. The Gmr cassette
was amplified using chromosomal DNA from PB12.SA3
as template and the expected product was confirmed by
PCR. Purified PCR products were used to inactivate pykA
in strain JM101. Selection of the resultant ΔpykA::gen
mutant was achieved on Gm containing plates and the
inactivation of pykA in Gmr colonies was confirmed by
PCR; the size of the PCR products was determined by
agarose gel electrophoresis. The ΔpykA::gen construction
was then P1 phage transduced to PB12.SA3; Gmr colonies
were selected and screened.
Transformation of derivative strains with plasmid pJLBaroGfbr 
tktA
The construction of plasmid pJLB aroGfbr tktA (Table 3)
has been previously reported [21,47]; this vector was used
to transform all SA producing derivative strains. Positive
clones were selected by growing colonies on LB plates
supplemented with tetracycline (Tet).
Cloning the aroB gene and transformation with plasmid 
pTOPOaroB
The  aroB  gene (1484 bp) was obtained by PCR using
chromosomal DNA from E. coli JM101 strain as template
and the primers FwaroB and RvaroB (Table s1, see Addi-
tional file 1). PCR reaction was performed with Pfu poly-
merase; the size of the PCR product was determined by
agarose gel electrophoresis and cloned directly into the
pCR®-Blunt II-TOPO® vector (Invitrogen, Carlsbad, USA)
leading to the construction of the pTOPOaroB plasmid
(Table 3). This vector was used to transform competent
TOP10 cells (Invitrogen) and selection was performed on
25 μg/mL of zeocin-containing LB plates. Functionality of
the cloned aroB gene was tested by restoring growth of an
aroB- E. coli mutant [48] in M9 minimal medium plates
supplemented with zeocin, as a consequence of the com-
plementation of the SA pathway in this mutant strain.
Cloning the aroE gene and transformation with plasmid 
pTOPOaroB aroE
The aroE gene (835 bp) was obtained by PCR using chro-
mosomal DNA from E. coli JM101 strain as template and
primers FwaroE and RvaroE (Table s1, see Additional file
1). PCR amplification was performed as described for the
aroB gene; the size of the PCR product was determined
by agarose gel electrophoresis. Amplified aroE gene and
plasmid pTOPOaroB were both digested with Bam HI
endonuclease. This vector was treated with calf intestine
phosphatase (Fermentas) and ligated with the digested
aroB product using T4 DNA ligase (Fermentas), trans-
formed into TOP10 competent cells and selection was
performed on zeocin-containing LB plates. Functionality
of the cloned aroE gene was tested by restoring growth of
an  aroE- E. coli mutant [48] in M9 minimal medium
plates supplemented with zeocin.
Cultivation media and growth conditions
Shake flask cultures inoculated with frozen stocks of each
strain were performed in 125 mL baffled flasks contain-
ing 10 mL of LB supplemented with the respective antibi-
otics as required: 30 μg/mL Km, 15 μg/mL Gm, 20 μg/mL
Cm or 30 μg/mL Tet (Table 3 shows specific antibiotic
resistances). Cultures were incubated overnight in a
shaker (New Brunswick Scientific, Edison, USA) at 37°C,
300 rpm. An aliquot of 150 μL from each culture was
used to inoculate a 250 mL baffled flask with 50 mL of
fermentation medium, whose composition has been pre-
viously reported for the production of SA, and grown as
described above. This medium contained 25 g/L of glu-
cose, 15 g/L of yeast extract [4] and the required antibiot-
ics. Biomass concentrations were determined and
calculations were performed to adjust inoculum size to
an OD600 nm of 0.35. Batch cultures were performed in
duplicate in an Applikon autoclavable glass Bio Reactor
(Schiedam, The Netherlands) 1 L fermentor (500 mL of
working volumen of fermentation medium supplemented
with the required antibiotics). This device was connected
to an Applikon ADI 1010 BioController and ADI 1025
controllers to monitor temperature, pH, impeller speed
and dissolved oxygen (DO). Batch fermentations were
run for 50 h at 37°C, pH 7.0 (maintained by addition of
3.0% NH4OH). An impeller speed of no less than 500 rpmEscalante et al. Microbial Cell Factories 2010, 9:21
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was used t o m a in ta in DO  l eve ls  a t  20%  ai r s a t u ra t io n.
Gene expression of cloned genes was induced by adding
0.1 mM IPTG at the onset of fermentation.
Analytical procedures
Biomass concentrations were monitored every hour dur-
ing the first 8 h of culture; after this point they were mon-
itored every 6 h until the end of the fermentation.
Samples (1.5 mL) were withdrawn from each reactor and
cell turbidity was determined spectrophotometrically at
600 nm (Beckman DU®-70 Spectrophotometer, Palo Alto,
USA). Samples for the determination of SA, DHS, QA,
and GA were prepared by centrifuging at 12,000 rpm for
1 min (Eppendorff Centrifuge 5410, Brinkman Instru-
ments Inc., Westubury, USA) 1 mL of fermented broth to
remove cells and filtered through 0.45 μM nylon mem-
branes (Millipore, Brazil). SA, DHS, QA, and GA concen-
trations were determined by HPLC using a Waters system
(600E quaternary pump, 717 automatic injector, 2410
refraction index, and 996 photodiode array detectors,
Waters, Milford, USA), equipped with an Aminex HPX-
87H column (300 × 7.8 mm; 9 μm) (Bio-Rad, Hercules,
USA) maintained at 50°C. The mobile phase was 5 mM
H2SO4, with a flow rate of 0.5 mL/min, at 50°C. All
metabolites were detected with a photodiode array detec-
tor at 210nm. DAHP concentrations were determined by
the thiobarbituric acid assay [49]. This method does not
distinguish between DAHP and DAH, so in this work,
DAHP levels corresponded the sum of both compounds
[26]. Glucose concentration was assessed by a biochemi-
cal analyzer (YSI 2700 Select, Yellow Springs, USA).
Calculations
The specific glucose (S) consumption rate (qs) was calcu-
lated during the exponential growth phase as the differ-
ential change in S with time (t) normalized to the biomass
concentration  . A predetermined correlation
factor (1 OD600 corresponded to 0.37 g/L of dry cellular
weight) [50] was used to transform OD600 values into cell
concentrations for qs calculation. TACY determinations
were based on the combined molar yields of DAHP, DHS,
SA, and GA [4].
In order to determine whether the observed differences
between growth, qs, and aromatic intermediate produc-
t i o n  ( D AHP ,  D HS,  S A  a n d  G A )  i n  s t r a i n  P B 1 2  a n d  i n
PB12.SA derivatives were significant (P < 0.05), an analy-
sis of variance (ANOVA) and the multiple comparison
test of Tukey's Honestly Significant Difference (HSD)
were performed using the XLSTAT program V2009.5.01
http://www.xlstat.com.
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